The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial (Hematowellness)
This multicenter, prospective, pilot randomized controlled trial aims to evaluate the feasibility and preliminary efficacy of a 16-week structured exercise program (SEP) in patients with hematologic malignancies, including acute myeloid leukemia, lymphoma, and multiple myeloma.
A total of 75 patients will be randomized in a 1:1 ratio to either a supervised exercise intervention or a control group receiving usual care and general advice on physical activity.
The intervention consists of a personalized, hybrid exercise program combining supervised home- and gym-based training, aerobic and resistance exercises, balance and stretching activities, and behavioral counseling.
The primary objective is to assess the feasibility of the intervention in terms of adherence to the exercise program and patient satisfaction.
Secondary objectives include evaluating intervention-related adverse events, patient-reported burden, health-related quality of life, fatigue, physical fitness, anthropometric parameters, and physical activity levels.
Assessments will be conducted at baseline, approximately 8 weeks, 16 weeks (end of intervention), and 24 weeks after randomization.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Bari、イタリア、70126
- まだ募集していません
- Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia
-
コンタクト:
- Carla Minoia
- 電話番号:+390805555905
- メール:carla.minoia1@gmail.com
-
Verona、イタリア、37134
- まだ募集していません
- Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
-
コンタクト:
- Carlo Visco
- 電話番号:+39045 8027488
- メール:carlo.visco@univr.it
-
-
Rm
-
Roma、Rm、イタリア、00133
- 募集
- Fondazione PTV Policlinico Tor Vergata
-
コンタクト:
- Maria Christina Cox
- 電話番号:+393382268017
- メール:chrisscox@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
**Inclusion Criteria:**
-
Patients aged between 18 and 75 years.
-
ECOG Performance Status ≤2.
-
Patients discharged after first-line intensive treatments (Category A), including:
- Acute myeloid leukemia (AML) in clinical remission following first-line intensive treatment (post-consolidation), within 30 days of hospital discharge, and not candidates for transplantation.
- Multiple myeloma in clinical remission following first-line treatment with autologous stem cell transplantation, within 30 days of hospital discharge.
- Lymphoma in clinical remission following first-line intensive treatment (e.g., CODOX-M/IVAC, HYPER-CVAD, DA-EPOCH, CHOP/DHAP, with or without autologous stem cell transplantation consolidation), within 30 days of hospital discharge.
-
Patients receiving or having received first-line treatment in an outpatient setting (Category B), including:
- Multiple myeloma in complete remission, having completed first-line treatment within the previous 30 days and undergoing maintenance therapy.
- Lymphoma patients undergoing first-line treatment with at least 12 weeks of therapy remaining.
-
Written informed consent provided.
**Exclusion Criteria:**
- Undergoing monotherapy with monoclonal antibodies.
- More than one line of systemic treatment.
- Estimated life expectancy of less than 6 months.
- Severe neurological illness.
- Lack of cardiology clearance or left ventricular ejection fraction below 50%.
- Unstable fractures or metastases inducing skeletal fragility, as determined by the treating hematologist, or recent femoral or vertebral fracture (within the previous 12 months).
- Serious active infection.
- Uncontrolled severe respiratory insufficiency or dependency on oxygen supplementation at rest or during exercise.
- Uncontrolled severe pain.
- Any other comorbidity contraindicating physical exercise.
- Any circumstances preventing adherence to study requirements or the ability to provide informed consent.
- Logistical barriers preventing adherence to the exercise program, as judged by the treating hematologist (e.g., distance from training locations, work commitments, or family circumstances).
- Regular engagement in physical activity according to current guidelines during the previous 6 months.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Structured Exercise Program (SEP)
Participants randomized to the intervention group will receive a 16-week personalized, supervised, hybrid structured exercise program (SEP), combining home- and gym-based training. The program includes aerobic, resistance, balance, and stretching exercises, a structured walking program, and behavioral counseling. Exercise sessions will be supervised by trained exercise professionals, either in person or remotely, according to the intervention phase. |
A 16-week structured and supervised exercise program tailored to the individual patient's clinical condition and physical abilities. The intervention includes aerobic exercise, resistance training, balance and flexibility exercises, walking activities, and behavioral counseling. Exercise sessions may be conducted in person or at home with remote supervision, according to the patient's needs and clinical status.
他の名前:
|
|
介入なし:Control
Participants randomized to the control group will receive usual care and general information about the benefits of physical activity. They will not participate in the supervised structured exercise program during the study period. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adherence to the Structured Exercise Program
時間枠:At 16 weeks (end of intervention)
|
Adherence will be assessed as the percentage of participants in the intervention group who attend at least 65% of the planned supervised exercise sessions. The intervention will be considered feasible if at least 70% of participants meet this adherence t |
At 16 weeks (end of intervention)
|
|
Patient Satisfaction With the Structured Exercise Program
時間枠:At 16 weeks (end of intervention)
|
Patient satisfaction will be assessed in the intervention group using the item "Overall, I am satisfied with the exercise program" from a study-specific satisfaction questionnaire. Responses are rated on a 4-point scale: "disagree", "somewhat disagree", "somewhat agree", and "agree". Satisfaction will be measured as the percentage of participants responding "somewhat agree" or "agree". The intervention will be considered feasible if at least 75% of participants meet this satisfaction criterion. |
At 16 weeks (end of intervention)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Health-Related Quality of Life (EORTC QLQ-C30)
時間枠:Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Changes in mean scores across all questionnaire scales will be compared between and within study groups. Scores are transformed to a 0-100 scale, with higher scores indicating better functioning or global health status on functional and global health scales, and greater symptom burden on symptom scales. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Change in Fatigue (FACIT-Fatigue)
時間枠:Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. Changes in mean fatigue scores will be compared between and within study groups at baseline, 8 weeks, and 16 weeks. Fatigue will also be assessed at 24 weeks for descriptive follow-up analyses. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Study Engagement Rate
時間枠:During the 18-month recruitment period.
|
The engagement rate will be calculated as the percentage of patients who agree to participate in the study among all patients invited to participate. Reasons for refusal will be documented to identify potential barriers to study participation. |
During the 18-month recruitment period.
|
|
Incidence of Intervention-Related Adverse Events
時間枠:Throughout the 16-week intervention period.
|
The number and severity of adverse events potentially related to the structured exercise program will be assessed in the intervention group. Adverse events will be monitored and recorded by exercise professionals and study personnel throughout the intervention period. Severity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
Throughout the 16-week intervention period.
|
|
Patient-Reported Burden of the Intervention (FACT-G Item GP5)
時間枠:At 8 weeks (T1) and 16 weeks (T2) after randomization.
|
Patient-Reported Burden of the Intervention (FACT-G Item GP5) |
At 8 weeks (T1) and 16 weeks (T2) after randomization.
|
|
Change in Physical Activity Levels (Godin-Shephard Questionnaire)
時間枠:Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Changes in physical activity levels will be assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire, which evaluates the frequency of mild, moderate, and vigorous physical activity performed during leisure time. Changes will be compared between and within study groups. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Non-Hematological Adverse Events
時間枠:Throughout the 16-week intervention period.
|
The prevalence of non-hematological adverse events of grade 3 or higher will be described and compared between the intervention and control groups. Adverse event severity will be classified according to CTCAE version 5.0. |
Throughout the 16-week intervention period.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。